


Supplemental Information



SUPPLEMENTAL FIGURE 2

Patient selection. Of 49 hospitals in the PHIS, 30 had complete administrative data for the years 2010-2020 and were included in the study.

SUPPLEMENTAL TABLE 3

Group No.	Mental Health Disorder Group
0	Not applicable
1	Accidental or undetermined poisoning
2	ADHD
3	Anxiety disorders
4	Autism spectrum disorder
5	Bipolar and related disorders
6	Communication disorders
7	Depressive disorders
8	Developmental delay or unspecified neurodevelopmental disorder
9	Disruptive, impulse control and conduct disorders
10	Dissociative disorders
11	Elimination disorders
12	Feeding and eating disorders
13	Fetal or newborn damage related to maternal substance abuse
14	Intellectual disability
15	Maternal mental illness or substance abuse during pregnancy, delivery or postpartum
16	Mental health symptom
17	Miscellaneous
18	Motor disorders
19	Neurocognitive disorders
20	Obsessive-compulsive and related disorders
21	Personality disorders
22	Schizophrenia spectrum and other psychotic disorders
23	Sexuality and gender identity disorders
24	Sleep-wake disorders
25	Somatic symptom and related disorders
26	Specific learning disorders
27	Substance abuse-related medical illness
28	Substance-related and addictive disorders
29	Suicide or self-injury
30	Trauma and stressor-related disorders

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

SUPPLEMENTAL TABLE 4 Medications Included in the Study Definition of Pharmacologic Restraint

Amobarbital	Midazolam
Aripiprazole	Olanzapine
Benztropine	Paliperidone
Chlordiazepoxide	Pentobarbital
Chlorpromazine	Phenobarbital
Dexmedetomidine	Prochlorperazine
Diazepam	Promazine
Diphenhydramine	Promethazine
Droperidol	Risperidone
Haloperidol	Thiopental
Hydroxyzine	Trifluoperazine
Ketamine	Triflupromazine
Lorazepam	Ziprasidone
Methohexital	

SUPPLEMENTAL TABLE 5 Multivariate analysis of pharmacologic restraint use among children of Black race

Visit Characteristic	Pharmacologic Restraint, OR (95% CI)
Age, y	
3–7	Referent
8–12	0.92 (0.78–1.1)
13–17	1.07 (0.89–1.28)
18–21	1.86 (1.47–2.36)
Sex	
Male	1.34 (1.22–1.48)
Ethnicity	
Hispanic	0.86 (0.72–1.03)
Payer	
Private	Referent
Public	1.1 (0.94–1.28)
Other	0.86 (0.65–1.13)
Time of day	
Day (8 AM–4 PM)	Referent
Evening (4 PM–12 AM)	0.99 (0.89–1.12)
Night (12 AM–8 AM)	1.34 (1.18–1.53)
Weekend visits	1.22 (1.14–1.3)
Repeat visit to the ED	1.54 (1.35–1.75)

SUPPLEMENTAL TABLE 6 Multivariate Analysis of Pharmacologic Restraint Use Among Visits With SMI

Visit Characteristic	Pharmacologic Restraint in Visits With SMI, OR (95% CI)	Pharmacologic Restraint in Visits Without SMI, OR (95% CI)
Age, y		
3–7	Referent	Referent
8–12	0.75 (0.54–1.04)	0.95 (0.84–1.06)
13–17	0.76 (0.62–0.94)	1.22 (1.03–1.44)
18–21	1.52 (1.09–2.11)	2 (1.68–2.38)
Sex		
Male	1.80 (1.61–2.02)	1.11 (1.04–1.20)
Race		
White	Referent	Referent
Black	2.13 (1.69–2.70)	1.06 (0.94–1.18)
Asian	1.61 (1.08–2.41)	0.95 (0.76–1.18)
Other	0.93 (0.68–1.28)	0.84 (0.72–0.98)
Ethnicity		
Latino	1.03 (0.82–1.29)	0.91 (0.76–1.10)
Payer		
Private	Referent	Referent
Public	1.33 (1.14–1.54)	1.02 (0.94–1.10)
Other	1.09 (0.84–1.40)	0.98 (0.68–1.41)
Time of day		
Day (8 AM–4 PM)	Referent	Referent
Evening (4 PM–12 AM)	0.96 (0.84–1.09)	1.02 (0.94–1.10)
Night (12 AM–8 AM)	1.58 (1.24–2.01)	1.64 (1.42–1.89)
Weekend visits	1.40 (1.29–1.53)	1.19 (1.15–1.24)
Repeat visit to ED	1.56 (1.30–1.88)	1.33 (1.19–1.48)